Mauritius vs Upper-middle income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc)

Mauritius
98.0%
in 2025
Upper-middle income (World Bank)
49.0%
in 2025
Mauritius rank
11th
Upper-middle income (World Bank) rank
10th

Pneumococcal conjugate second or third-dose vaccines (PCVc) over time

  • Mauritius
  • Upper-middle income (World Bank)
020406080100200820162025

How they compare

Mauritius currently reports 98.0% against 49.0% in Upper-middle income (World Bank), a difference of 49.0%.

That makes Mauritius's figure about 2.0 times Upper-middle income (World Bank)'s.

The two have swapped places 1 time across 18 shared years of data; in 2008 it was Upper-middle income (World Bank) ahead.

Mauritius ranks 11th and Upper-middle income (World Bank) ranks 10th of 194 countries.

Across the 3 decades both report, Mauritius averaged higher in 2 and Upper-middle income (World Bank) in 1.

Head to head by decade

Decade Mauritius Upper-middle income (World Bank) Difference Ahead
2000s 0.0% 3.0% 3.0% Upper-middle income (World Bank)
2010s 28.7% 22.9% 5.8% Mauritius
2020s 95.0% 38.8% 56.2% Mauritius

Averages of every year both report within each decade.

Frequently asked questions

Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mauritius or Upper-middle income (World Bank)?
Mauritius, at 98.0% against 49.0% in Upper-middle income (World Bank) as of 2025.
What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mauritius and Upper-middle income (World Bank)?
49.0%, with Mauritius ahead.
How many years of comparable data are there for Mauritius and Upper-middle income (World Bank)?
18 years are reported by both, from 2008 to 2025.
How do Mauritius and Upper-middle income (World Bank) rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
Mauritius ranks 11th and Upper-middle income (World Bank) ranks 10th of 194 countries.
Where does this data come from?
World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Mauritius vs Upper-middle income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc). Statizoid, drawing on World Health Organization, Global Health Observatory. Retrieved 28 August 2026, from https://health.statizoid.com/compare/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/mauritius/upper-middle-income-world-bank/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY-NC-SA 3.0 IGO (WHO); please keep the attribution.

<a href="https://health.statizoid.com/compare/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/mauritius/upper-middle-income-world-bank/">Mauritius vs Upper-middle income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc)</a> — Statizoid

About this data

Indicator
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC)
Source
World Health Organization, Global Health Observatory
Licence
CC BY-NC-SA 3.0 IGO (WHO)
Coverage
206 places, 3,705 data points, 2008–2025
Last refreshed